Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Mark M. Zalupski

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2114-9352; OpenAlex author ID A5011595369. Sources: ClinicalTrials.gov.

Their work

Papers
23 (first author 1, last author 5)
Trials
8 (principal investigator on 8)
Grants
0
Labs led
1
Collaborators
100
Papers, trials and grants by year

2004: 2 trials · 2005: none · 2006: 1 trial · 2007: 1 trial · 2008: none · 2009: none · 2010: 1 trial · 2011: 2 trials · 2012: 3 papers, 1 trial · 2013: 3 papers · 2014: 5 papers · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 2 papers

Papers 23

  1. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreat… Co-author DOI 10.1016/j.ejca.2024.113950↗
  2. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-0499↗
  3. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resec… Last author DOI 10.1016/j.ijrobp.2019.08.057↗
  4. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. Co-author DOI 10.3389/fonc.2020.01112↗
  5. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic C… Co-author DOI 10.1200/jco.19.00730↗
  6. Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy. Last author DOI 10.1016/j.ijrobp.2017.10.030↗
  7. A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve… First author DOI 10.1097/coc.0000000000000260↗
  8. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancrea… Co-author DOI 10.1200/jco.2017.74.9564↗
  9. Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy. Co-author DOI 10.1097/coc.0000000000000200↗
  10. A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. Last author DOI 10.1007/s10637-016-0376-1↗
  11. Implication of suspicious cytology in endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer. Co-author DOI 10.1007/s12029-014-9681-0↗
  12. Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Co-author DOI 10.1038/srep10867↗
  13. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective tria… Co-author DOI 10.1002/cncr.28648↗
  14. Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or bor… Co-author DOI 10.1016/j.ijrobp.2014.05.053↗
  15. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Co-author DOI 10.1016/j.tranon.2014.07.005↗
  16. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-1269↗
  17. DEPTOR has growth suppression activity against pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.2659↗
  18. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy:… Co-author DOI 10.1002/cncr.27734↗
  19. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Last author DOI 10.1002/cncr.28117↗
  20. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiati… Co-author DOI 10.1016/j.ijrobp.2012.11.020↗
  21. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2011.08.022↗
  22. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pa… Last author DOI 10.1016/j.ijrobp.2012.02.051↗
  23. A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. Co-author PMID 23112883↗

Trials 8

  1. A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer Principal investigator NCT01663272↗
  2. A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients Principal investigator NCT01661088↗
  3. A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers Principal investigator NCT01661114↗
  4. Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer Principal investigator NCT01195415↗
  5. Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer Principal investigator NCT00456599↗
  6. Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer Principal investigator NCT00593866↗
  7. Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer Principal investigator NCT00242190↗
  8. Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma Principal investigator NCT00327327↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Theodore Steven Lawrence · 9 shared papers, 2012–2020 · strength 0.49
  2. Vaibhav Sahai · 5 shared papers, 2014–2024 · strength 0.45
  3. Edgar Ben‐Josef · 9 shared papers, 2012–2018 · strength 0.37
  4. Wells A. Messersmith · 2 shared papers, 2024 · strength 0.32
  5. Kyle Clifford Cuneo · 4 shared papers, 2014–2020 · strength 0.31
  6. Edward Jae-Hoon Kim · 5 shared papers, 2013–2020 · strength 0.27
  7. Diane M. Simeone · 6 shared papers, 2012–2017 · strength 0.25
  8. Meredith Ann Morgan · 3 shared papers, 2015–2019 · strength 0.21
  9. Tanios Bekaii‐Saab · 5 shared papers, 2013–2015 · strength 0.19
  10. Hari Nathan · 2 shared papers, 2019–2020 · strength 0.19
  11. Clifford S. Cho · 2 shared papers, 2019–2020 · strength 0.19
  12. Taichi Kawabe · 1 shared paper, 2024 · strength 0.17
  13. Donald Richards · 1 shared paper, 2024 · strength 0.17
  14. Thomas Enzler · 1 shared paper, 2024 · strength 0.17
  15. Jiaqi Shi · 2 shared papers, 2015–2020 · strength 0.16
  16. Michael James Overman · 1 shared paper, 2024 · strength 0.16
  17. Nick Pavlakis · 1 shared paper, 2024 · strength 0.16
  18. Mariano Ponz‐Sarvisé · 1 shared paper, 2024 · strength 0.16
  19. Niharika B. Mettu · 1 shared paper, 2024 · strength 0.16
  20. Adnan M. Nagrial · 1 shared paper, 2024 · strength 0.16
  21. David Robert Spigel · 1 shared paper, 2024 · strength 0.16
  22. Andrew L. Coveler · 1 shared paper, 2024 · strength 0.16
  23. Matthew J. Reilley · 1 shared paper, 2024 · strength 0.16
  24. Christos K Fountzilas · 1 shared paper, 2024 · strength 0.16
  25. Anne M. Noonan · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.